Literature DB >> 18651836

Glucokinase and molecular aspects of liver glycogen metabolism.

Loranne Agius1.   

Abstract

Conversion of glucose into glycogen is a major pathway that contributes to the removal of glucose from the portal vein by the liver in the postprandial state. It is regulated in part by the increase in blood-glucose concentration in the portal vein, which activates glucokinase, the first enzyme in the pathway, causing an increase in the concentration of glucose 6-P (glucose 6-phosphate), which modulates the phosphorylation state of downstream enzymes by acting synergistically with other allosteric effectors. Glucokinase is regulated by a hierarchy of transcriptional and post-transcriptional mechanisms that are only partially understood. In the fasted state, glucokinase is in part sequestered in the nucleus in an inactive state, complexed to a specific regulatory protein, GKRP (glucokinase regulatory protein). This reserve pool is rapidly mobilized to the cytoplasm in the postprandial state in response to an elevated concentration of glucose. The translocation of glucokinase between the nucleus and cytoplasm is modulated by various metabolic and hormonal conditions. The elevated glucose 6-P concentration, consequent to glucokinase activation, has a synergistic effect with glucose in promoting dephosphorylation (inactivation) of glycogen phosphorylase and inducing dephosphorylation (activation) of glycogen synthase. The latter involves both a direct ligand-induced conformational change and depletion of the phosphorylated form of glycogen phosphorylase, which is a potent allosteric inhibitor of glycogen synthase phosphatase activity associated with the glycogen-targeting protein, GL [hepatic glycogen-targeting subunit of PP-1 (protein phosphatase-1) encoded by PPP1R3B]. Defects in both the activation of glucokinase and in the dephosphorylation of glycogen phosphorylase are potential contributing factors to the dysregulation of hepatic glucose metabolism in Type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18651836     DOI: 10.1042/BJ20080595

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  125 in total

1.  Thermal stability of glucokinase (GK) as influenced by the substrate glucose, an allosteric glucokinase activator drug (GKA) and the osmolytes glycerol and urea.

Authors:  B Zelent; C Buettger; J Grimsby; R Sarabu; J M Vanderkooi; A J Wand; F M Matschinsky
Journal:  Biochim Biophys Acta       Date:  2012-03-16

2.  Crystal structure of hexokinase KlHxk1 of Kluyveromyces lactis: a molecular basis for understanding the control of yeast hexokinase functions via covalent modification and oligomerization.

Authors:  E Bartholomeus Kuettner; Karina Kettner; Antje Keim; Dmitri I Svergun; Daniela Volke; David Singer; Ralf Hoffmann; Eva-Christina Müller; Albrecht Otto; Thomas M Kriegel; Norbert Sträter
Journal:  J Biol Chem       Date:  2010-10-12       Impact factor: 5.157

3.  Glucokinase activation repairs defective bioenergetics of islets of Langerhans isolated from type 2 diabetics.

Authors:  Nicolai M Doliba; Wei Qin; Habiba Najafi; Chengyang Liu; Carol W Buettger; Johanna Sotiris; Heather W Collins; Changhong Li; Charles A Stanley; David F Wilson; Joseph Grimsby; Ramakanth Sarabu; Ali Naji; Franz M Matschinsky
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-09-27       Impact factor: 4.310

4.  Mutational analysis of allosteric activation and inhibition of glucokinase.

Authors:  Bogumil Zelent; Stella Odili; Carol Buettger; Dorothy K Zelent; Pan Chen; Deborah Fenner; Joseph Bass; Charles Stanley; Monique Laberge; Jane M Vanderkooi; Ramakanth Sarabu; Joseph Grimsby; Franz M Matschinsky
Journal:  Biochem J       Date:  2011-12-01       Impact factor: 3.857

5.  Association with nitric oxide synthase on insulin secretory granules regulates glucokinase protein levels.

Authors:  Michele L Markwardt; Andongfac Nkobena; Shi-Ying Ding; Mark A Rizzo
Journal:  Mol Endocrinol       Date:  2012-07-06

6.  Glucose autoregulation is the dominant component of the hormone-independent counterregulatory response to hypoglycemia in the conscious dog.

Authors:  Justin M Gregory; Noelia Rivera; Guillaume Kraft; Jason J Winnick; Ben Farmer; Eric J Allen; E Patrick Donahue; Marta S Smith; Dale S Edgerton; Phillip E Williams; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-05-16       Impact factor: 4.310

Review 7.  Molecular and cellular regulation of human glucokinase.

Authors:  Shawn M Sternisha; Brian G Miller
Journal:  Arch Biochem Biophys       Date:  2019-01-11       Impact factor: 4.013

8.  ChREBP regulates fructose-induced glucose production independently of insulin signaling.

Authors:  Mi-Sung Kim; Sarah A Krawczyk; Ludivine Doridot; Alan J Fowler; Jennifer X Wang; Sunia A Trauger; Hye-Lim Noh; Hee Joon Kang; John K Meissen; Matthew Blatnik; Jason K Kim; Michelle Lai; Mark A Herman
Journal:  J Clin Invest       Date:  2016-09-26       Impact factor: 14.808

9.  Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes.

Authors:  D J Baker; G P Wilkinson; A M Atkinson; H B Jones; M Coghlan; A D Charles; B Leighton
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

Review 10.  Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patient.

Authors:  Charmaine D Rochester; Oluwaranti Akiyode
Journal:  World J Diabetes       Date:  2014-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.